ライフサイエンスコーパス: lung function

1 o assess effects of anemia or transfusion on lung function).

2 fitness was associated with less decline in lung function.

3 al FEV1 but experienced the greatest loss of lung function.

4 ergic airway inflammation and improvement of lung function.

5 a higher rate of tobacco smoking, and lower lung function.

6 tization with respect to atopic diseases and lung function.

7 diagnosed asthma and the effect of asthma on lung function.

8 ropy between nicotine dependence and COPD or lung function.

9 le long-term effects on allergic disease and lung function.

10 poorly controlled asthma, including reduced lung function.

11 d lactate content correlated negatively with lung function.

12 with increased asthma symptoms and decreased lung function.

13 with increased exacerbations but with normal lung function.

14 way neutrophilia that correlated with better lung function.

15 ica and assess the impact of malnutrition on lung function.

16 increased IL-8 concentrations, and impaired lung function.

17 ct persistent effects of maternal smoking on lung function.

18 BEC donors completed spirometry to measure lung function.

19 oms and may result in a sustained decline in lung function.

20 uality of life, inflammatory biomarkers, and lung function.

21 rstitial remodelling, leading to compromised lung function.

22 hether small molecule changes correlate with lung function.

23 function at 1 year, independent of baseline lung function.

24 s to hypobaric hypoxia, possibly by altering lung function.

25 activation, mediator release, and changes in lung function.

26 s linked to allergic airway inflammation and lung function.

27 ed for subsequent development of compromised lung function.

28 nthocyanin intake and age-related decline in lung function.

29 acerbations and related to mortality and low lung function.

30 gE production and directly affected impaired lung function.

31 ss the full ranges associated with childhood lung function.

32 contribution of lung inflammation to loss in lung function.

33 y properties, affects longitudinal change in lung function.

34 ction or whether respiratory illness reduces lung function.

35 ng IL-17A dampened inflammation and restored lung function.

36 he airway epithelium is essential for normal lung function.

37 , and retrospective studies suggest improved lung function.

38 rphisms in Atg5 which correlate with reduced lung function.

39 NPs) have identified 55 SNPs associated with lung function.

40 ree were quantified as a measure of regional lung function.

41 cell progenitors than asthmatics with normal lung function.

42 ice with allergic asthma and restored normal lung function.

43 asthma, worsen disease symptoms, and impair lung function.

44 these mice was not associated with impaired lung function.

45 lop interventions for children with impaired lung function.

46 nflammation, and osteoporosis and may impair lung function.

47 bleomycin-induced lung fibrosis and improved lung function.

48 thickening, increased stiffness and impaired lung function.

49 but this did not result in slower decline in lung function.

50 e at-risk polymorphism on postbronchodilator lung function.

51 with improvements in short-term or long-term lung function.

52 as associated with greater annual decline in lung function.

53 used by the virus must be repaired to regain lung function.

54 ildren who do progress to persistent asthma, lung function abnormalities and airway remodelling can a

55 therapy in terms of the following: improving lung function; achieving asthma control and reducing sym

56 tment, or death) and change from baseline in lung function after bronchodilator.

57 Early decline in lung function after normal growth is associated with a g

58 A/X31 H3N2 led to prolonged deterioration of lung function, aggravated mucus production, peri-vascula

59 for asthma; hay fever; eczema; and impaired lung function, also in children without an established a

60 the effect of copy number variants (CNVs) on lung function, although CNVs represent a significant pro

61 d whether such patterns were associated with lung function among BEC donors.

62 arked decrease in pathophysiology, including lung function and airway eosinophilia induced by Alterna

63 elf-reported symptoms, but associations with lung function and allergic sensitization have been minim

64 Inflammatory biomarkers, lung function and an IgE fungal panel to colonising fila

65 ngioleiomyomatosis correlating with impaired lung function and angiomyolipoma presence.

66 l age, and infant weight gain with childhood lung function and asthma (age range, 3.9-19.1 years).

67 ast compared with montelukast alone improved lung function and asthma control in patients with modera

68 poral fluctuations have been demonstrated in lung function and asthma control, but the effect of cont

69 Associations between childhood lung function and asthma/COPD/ACOS were examined using m

70 Poor lung function and comorbidities were predictive of poor

71 everage large data sets of smoking behavior, lung function and COPD, and addressed two questions, (1)

72 of insight that static imaging provides for lung function and dysfunction, the limited resolution of

73 the effects of once-daily triple therapy on lung function and health-related quality of life with tw

74 lated to patterns of airway inflammation and lung function and identify molecular markers for neutrop

75 y disease (COPD) is characterized by reduced lung function and is the third leading cause of death gl

76 lung alveolar in mammals is vital for proper lung function and its deficiency is related to a range o

77 Childhood impairment of lung function and male sex were the most significant pre

78 tate is made by combination of monitoring of lung function and more directly by assessing the lung st

79 ermine whether the association between lower lung function and mortality would be stronger in those w

80 macaftor/ivacaftor has been shown to improve lung function and other endpoints in patients aged 12 ye

81 Air pollution adversely influences lung function and PC20 in asthmatic children.

82 atory tract illness is important to optimize lung function and promote respiratory health in childhoo

83 The FULFIL (Lung Function and Quality of Life Assessment in Chronic

84 nd statistically significant improvements in lung function and quality of life at 6 months, with an a

85 onary exacerbations, which lead to decreased lung function and reduced quality of life.

86 Dupilumab increased lung function and reduced severe exacerbations in patien

87 een developed and are effective in improving lung function and reducing pulmonary exacerbations.

88 eralized estimating equation models assessed lung function and symptom relationships with the tempora

89 ermine the effect of indoor classroom NO2 on lung function and symptoms in inner-city school children

90 nce-daily tiotropium Respimat 5 mug improved lung function and was well tolerated as add-on therapy t

91 ucose tolerance is associated with decreased lung function and worsened outcomes.

92 q13.2) were associated with smoking adjusted lung function, and 15q25.1 reached genome-wide significa

93 s associated with concurrent asthma, altered lung function, and allergic sensitization in children.

94 sus placebo for severe asthma exacerbations, lung function, and asthma symptom control across subgrou

95 nical parameters of cough and sputum scores, lung function, and chest high-resolution computed tomogr

96 ncreased frequency of exacerbations, reduced lung function, and corticosteroid responsiveness.

97 nobese asthmatics, such as disease severity, lung function, and eosinophilic inflammation.

98 enes than do cells from children with normal lung function, and expression of interferon-associated g

99 multidomain approach incorporating symptoms, lung function, and inflammation to determine steroid res

100 cts were monitored for respiratory symptoms, lung function, and nasal viral load.

101 Furthermore, chest x-rays, lung function, and PaO2/FIO2 ratios did not differ betwe

102 to measure the associations between ND-E/I, lung function, and respiratory morbidity.

103 attenuated lung tissue destruction, improved lung function, and restored expression of beta-catenin-d

104 differences in measures of quality of life, lung function, and the distance walked in 6 minutes.

105 justed for age, height, race-sex group, peak lung function, and years from peak lung function, each a

106 performance, more than 10% weight loss, poor lung function, and/or oxygen dependence were included, p

107 nicotine dependence influence COPD risk and lung function; and (2) the genetic pleiotropy follow cau

108 oup were also accompanied by improvements in lung function, antiinflammatory biomarkers, and vitamin

109 with persistent asthma and reduced growth of lung function are at increased risk for fixed airflow ob

110 cts of exposures to ambient air pollution on lung function are well documented, but evidence in racia

111 th statistically significant improvements in lung function, as measured by LCI2.5 and ppFEV1, versus

112 with allergic diseases, skin prick tests and lung function assessed at 12 and 18 years were estimated

113 ted adjusted differences in annual change in lung function associated with each flavonoid subclass, c

114 ttenuating the effect of HRV-16 challenge on lung function, asthma control, and symptoms in asthmatic

115 life lower respiratory tract illness impairs lung function at 1 year, independent of baseline lung fu

116 aturity were other independent predictors of lung function at 1 year.

117 p to 18 years, and sensitization and reduced lung function at 12 years.

118 ed in the Drakenstein child health study had lung function at 6 weeks and 1 year.

119 Tobacco smoke exposure, lung function at 6 weeks, infant growth, and prematurity

120 gen therapy during the newborn period and in lung function at 8 years of age in children whose birth

121 itisation and total IgE at 7 years, and with lung function at 8-9 years in the offspring, after contr

122 Being in the lowest quartile for lung function at age 7 may have long-term consequences f

123 um and breast milk with allergic disease and lung function at ages 12 and 18 years.

124 ients who have undergone close monitoring of lung function before, during, and after treatment with B

125 mination included measures of anthropometry, lung function, blood pressure and standard blood-based b

126 Secondary outcomes included quality of life, lung function, body composition, aerobic capacity, muscl

127 s and blood eosinophil counts in relation to lung function, bronchial hyperresponsiveness (BHR), and

128 hms at age 7 years along with assessments of lung function, bronchial responsiveness, fraction of exh

129 to higher prevalence of asthma and decreased lung function, but not with hay fever or biomarkers of a

130 enzyme inhibitor therapy improves renal and lung function by reducing endothelial injury.

131 , including respiratory infections, impaired lung function, cardiac infarctions, and cancers.

132 Lung function, central and peripheral airway remodelling

133 etic pleiotropy between smoking behavior and lung function/chronic obstructive pulmonary disease (COP

134 fibrosis are at risk for prolonged drops in lung function, clinically termed rapid decline, during d

135 en TRAP exposure and allergic sensitization, lung function, current wheeze, and asthma (n = 1405) wer

136 ral self-similarity (alpha) of more variable lung function (CVpef) is associated with treatment failu

137 xacerbations are associated with progressive lung function decline and increased mortality in cystic

138 eptor (uPAR/PLAUR) have been associated with lung function decline and uPAR blood levels in asthma su

139 Lung function decline has not previously been investigat

140 ithelial cells may be a mechanism leading to lung function decline in a subset of children with asthm

141 OH)D levels were weakly associated with more lung function decline in adults with asthma, and stronge

142 ctivity and desmosine with exacerbations and lung function decline in bronchiectasis.

143 on has no major short-term effect on rate of lung function decline in HIV-positive individuals who ar

144 n smokers without airflow obstruction affect lung function decline is unknown.

145 and with future exacerbations, mortality and lung function decline over 3 years.

146 Associations with lung function decline were investigated using linear mix

147 dose budesonide decreases SARE risk, reduces lung function decline, and improves symptom control simi

148 dose budesonide decreases SARE risk, reduces lung function decline, and improves symptom control simi

149 To study whether lung function decline, assessed by FVC and FEV1, is acce

150 o 2.7; 95% CI, 1.42-5.29; P = 0.003) but not lung function decline.

151 eas and this lung at risk is associated with lung function decline.

152 -3-ol intake was also associated with slower lung function decline.

153 mass is a CT-based biomarker of accelerated lung function decline.

154 phenotype of occupational endotoxin-related lung function decline.

155 ausal status was associated with accelerated lung function decline.

156 Lung function declined more rapidly among transitional a

157 ughout life might help to reduce progressive lung function decrease and disease severity in adulthood

158 cy of respiratory symptoms increase, whereas lung function decreases with increased ozone exposure in

159 35 ppb or greater (OR range, 3.82-6.24), and lung function decrements (mean range of differences: -0.

160 pollution during infancy has been related to lung function decrements in 8-year-old children, but whe

161 air pollution emissions are associated with lung function deficits in nonfarming residents.

162 ts demonstrate the applicability of regional lung function derived from lung motion as an effective a

163 chnique, whereas age and cognition with poor lung function distinguished those with poor adherence an

164 3 individuals, selected from extremes of the lung function distribution in UK Biobank, and follow-up

165 titutions were found in six genes related to lung function, DNA repair, and angiogenesis in the high-

166 ncluding lower respiratory tract illness, on lung function during infancy.

167 esulted in clinically meaningful benefits in lung function, dyspnea, exercise tolerance, and quality

168 oup, peak lung function, and years from peak lung function, each additional minute of treadmill durat

169 ead to an increase in the rate of decline of lung function, especially in older individuals and in th

170 n clinically meaningful benefits of improved lung function, exercise tolerance, and quality of life.

171 ry outcome was the annual rate of decline in lung function, expressed as the FEV1 slope in mL/year; s

172 No associations were observed with reduced lung function (FEV1 % of predicted value < 90%).

173 nts with paucigranulocytic asthma had better lung function (FEV1 % pred) [median (IQR): 71.5 (59.0-88

174 Measures of lung function (FEV1, forced vital capacity [FVC], and fo

175 , reduces asthma exacerbations, and improves lung function for patients with severe eosinophilic asth

176 ntly reduce asthma exacerbations and improve lung function for patients with severe, uncontrolled ast

177 history, family history of lung cancer, and lung function (forced expiratory volume in 1 second [FEV

178 , walking in Hyde Park led to an increase in lung function (forced expiratory volume in the first sec

179 -specific IgE >/= 0.35 kUA /L) (n = 418) and lung function [forced expiratory volume in one second (F

180 creased the yield of independent signals for lung function from 54 to 97.

181 hR phosphorylation (which include control of lung function) from those responses that are downstream

182 at were previously classified by patterns of lung function growth and decline (normal growth, normal

183 according to four characteristic patterns of lung-function growth and decline on the basis of graphs

184 dictors of abnormal longitudinal patterns of lung-function growth and decline.

185 Furthermore, asthmatics with reduced lung function had a higher frequency of Lin(-) CD34(hi)

186 No robust associations were observed with lung function, haemoglobin, creatinine, glucose levels o

187 lusion A risk prediction model that includes lung function has strong predictive ability, which could

188 orrelated with physiological measurements of lung function (i.e., forced expiratory volumes and diffu

189 lyses showed that the strongest predictor of lung function impairment in asthmatic patients was %WA,

190 n asthmatic patients and patients with COPD, lung function impairment is strongly associated with air

191 ed 3 clusters with mild, moderate, or severe lung function impairment with corresponding decreased lu

192 uctive Lung Disease spirometric criteria for lung-function impairment that was consistent with chroni

193 ctual and future risk), quality of life, and lung function improved after starting continuous positiv

194 Although the lung function improvement observed does not warrant use

195 sures to POPs and allergic sensitization and lung function in 20-year-old offspring.

196 pollutant emissions from livestock farms and lung function in a general, nonfarming, rural population

197 date have assessed the predictive ability of lung function in a population-based cohort.

198 genome-wide association studies of CNV with lung function in a subset of 4 cohorts (n < =12,403) wit

199 To investigate the role of childhood lung function in adult COPD phenotypes.

200 c sensitization, current asthma, and reduced lung function in adults, and whether these associations

201 Alterations in lung function in aging and Sftpd -/- mice have been infe

202 Our results showed marked heterogeneous lung function in beta-ENaC-Tg mice compared to wild-type

203 LCI identified significant deterioration of lung function in CF over time.

204 t 36 weeks and no significant improvement in lung function in childhood over time.

205 o identify genetic variants whose effects on lung function in children with asthma are modified by th

206 e (NO2) causes asthma symptoms and decreased lung function in children with asthma.

207 ed with allergic airway diseases and reduced lung function in children, but evidence concerning adult

208 e of these 13 loci have been associated with lung function in general population samples, while 4 (EE

209 immediate versus deferred ART on decline in lung function in HIV-positive individuals.

210 ix deposition results in progressive loss of lung function in IPF.

211 between exposure to particulates and reduced lung function in minority children in which racial/ethni

212 ht help to explain why TNF blockade improves lung function in only some patients with asthma.

213 derived allele of GPR126 is associated with lung function in our sample of highlanders (p < 0.05).

214 ulmonary inflammation and associated loss of lung function in patients with CF.

215 been shown to provide modest improvements in lung function in patients with mild-to-moderate asthma,

216 udinal measurements of growth and decline in lung function in patients with persistent childhood asth

217 ne conductance regulator (CFTR) activity and lung function in people with cystic fibrosis and G551D-C

218 Screening of lung function in school age children may identify a high

219 nd are associated with asthma and with worse lung function in subjects with asthma.

220 y, airway microbiology and inflammation, and lung function in subjects with cystic fibrosis and chron

221 lifelong consequences this has on offspring lung function, including the increased risk of childhood

222 RATIONALE: Global Lung Function Initiative recommends reporting lung funct

223 RATIONALE: The rate of decline of lung function is greater than age-related change in a su

224 m cytokines and chemokines, total serum IgE, lung function (LF), and airway hyper-responsiveness (AHR

225 xacerbations are associated with accelerated lung function loss in subjects with established COPD, pa

226 ly targeted for subgroups at highest risk of lung function loss.

227 , attenuated injury progression and improved lung function (lung volume and compliance; P < 0.05 comp

228 and eczema were diagnosed prospectively, and lung function measured at age 1 month and 7 years.

229 luding asthma-associated health care use and lung function, measured by forced expiratory volume in 1

230 in a subset of 4 cohorts (n < =12,403) with lung function measurements and meta-analysed the results

231 low 25(OH)D (<50 nmol/L) had more decline in lung function measurements for forced expiratory volume

232 Lung function measurements, and bronchoalveolar lavage f

233 tent, physician-diagnosed asthma verified by lung function measurements.

234 eter and ammonia (NH3) concentrations before lung function measurements.

235 ung Function Initiative recommends reporting lung function measures as z-score, and a classification

236 sed a new diagnostic algorithm applying four lung function measures sequentially (ratio of forced exp

237 We developed a lung function monitoring point-of-care-testing device (L

238 ere the pleiotropic variants directly affect lung function, not mediated by influencing subjects' smo

239 rements (questionnaires, urine cotinine, and lung function) only.

240 olled asthma despite having little effect on lung function or airway inflammation.

241 ts nor were blood fibrocytes associated with lung function or qCT, but were increased in eosinophilic

242 there was no effect modification of atopy on lung function or symptom outcomes.

243 e predisposed to illness because of impaired lung function or whether respiratory illness reduces lun

244 ally acute, Koch phenomenon-like reactions), lung function, or radiology attributable to vaccine were

245 o associations were detected with respect to lung function outcomes or allergic sensitization at 18 t

246 s in smokers without COPD) and the change in lung function over 5 years of follow-up.

247 ed data on factors associated with change in lung function over time.

248 incident AF after additional adjustment for lung function (P=0.02 for both).

249 Lung function parameters (forced vital capacity (FVC), p

250 The evolution of lung function parameters over time and the difference be

251 In the omalizumab responder patients, lung function parameters were also obtained at 12, 18, a

252 To compare different lung function parameters, Pearson correlation coefficien

253 terest were anthropometry, body composition, lung function, physical capacity (hand grip, step test,

254 ood disorders, exacerbations, comorbidities, lung function, prescribed treatment, and survival.

255 lying on documented reversible impairment of lung function (primary endpoint).

256 t 6 and 12 months in the 6-minute walk test, lung function, quality of life as assessed by St George'

257 ignaling in bronchial airway contraction and lung function regulated through the M3-muscarinic acetyl

258 e costs, but whether they accelerate loss of lung function remains controversial.

259 es (blood pressure, heart rate, body weight, lung function, respiratory symptoms, exhaled breath nitr

260 To test associations between serum MMP-7 and lung function, respiratory symptoms, interstitial lung a

261 ssociated with: weaker grip strength, poorer lung function, slower walking speed, lower fluid intelli

262 tissue and BAL from healthy controls, normal lung function smokers (NLFS), and COPD subjects.

263 ddition, inhibition of BET proteins improved lung function (specifically quasi-static lung compliance

264 We measured lung function, sputum bacterial content, and inflammatio

265 nalyzing whole-genome genotyping data from a lung function study.

266 dose groups compared with placebo across all lung function subgroups.

267 Annual asthma exacerbation rates, lung function, symptoms, and safety were assessed.

268 s use, tobacco use was associated with worse lung function, systemic inflammation, and metabolic heal

269 fibrosis leads to an irreversible decline in lung function termed bronchiolitis obliterans syndrome (

270 g cancer, CEA and AFP for light smokers, and lung function test (Maximum Mid-Expiratory Flow, MMEF25-

271 A lung function test and a methacholine challenge test wer

272 tion of participants with a current positive lung function test at each step of the algorithm, and re

273 correlations were observed for all evaluated lung function test parameters compared with median and i

274 Follow-up lung function testing in adulthood is vital for these in

275 predict, especially in young children and by lung function testing, which may be affected by multiple

276 week periods twice per year, coinciding with lung function testing.

277 alues for spirometry, the order in which the lung function tests are done, and the position of bronch

278 is, we conducted whole genome sequencing and lung function tests in 19 Argentinean highlanders (>3500

279 a typical history of asthmatic symptoms and lung function tests.

280 monitoring would result in slower decline in lung function than in control subjects.

281 are increased and associated with preserved lung function through a small airway-dependent mechanism

282 ke fibrocytes was positively associated with lung function through associations with air trapping, pr

283 importance of specific loci associated with lung function to COPD, and identify potential regions of

284 ive p-value thresholds, the smoking adjusted lung function traits share association signals with ciga

285 of FEV1 to FVC was used to identify distinct lung function trajectories among participants with two o

286 ndividuals with a distinct, persistently low lung function trajectory in the CRS (Tucson Children's R

287 d population demonstrates a persistently low lung function trajectory that may be partly established

288 adult smoking can negatively influence adult lung function trajectory, but few studies consider how t

289 nd internally validate a model incorporating lung function using data from the UK Biobank prospective

290 Lung function was available and normal for 6 patients.

291 h ischemic heart disease who were recruited, lung function was defined for 2,730 patients.

292 ry fitness and covariate adjusted decline in lung function was evaluated.

293 week, pinteraction=0.11), prebronchodilator lung function was higher, and symptom-free days were mor

294 0.94), and the decline in postbronchodilator lung function was less at 3 years' follow-up (pinteracti

295 The effect of atopy on lung function was no longer apparent when participants w

296 ion analysis of dust mite allergen level and lung function was performed in a cohort of Puerto Rican

297 Lung function was significantly better in lung grafts on

298 Multinomial regression demonstrated that lung function was significantly diminished among childre

299 Lung function was tested in 648 children at 1 year.

300 tration, histological damage, and decline in lung function were quantified.